Evidence grade: WEAK — Supported only by weak or preliminary evidence.
Recurrence occurs at non-enhancing infiltrative margins that current enhancement-based RANO and segmentation largely ignore; this is where patients actually fail.
RANO 2.0 de-emphasizes T2/FLAIR to reduce noise, but infiltrative progression is clinically real and undermeasured.
Develop and validate reproducible non-enhancing burden metrics vs recurrence location ground truth; inter-reader and test-retest repeatability first.
This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.